MYGN vs TRIB
Myriad Genetics Inc. and Trinity Biotech PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MYGN | TRIB |
|---|---|---|
| Revenue | $824.5M | $61.6M |
| Net income | $-365.9M | $-31.8M |
| Gross margin | 69.9% | 34.8% |
| Net margin | −44.4% | −50.7% |
| Return on equity | −68.5% | · |
| Diluted EPS | −$3.95 | · |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | $-4.6M |
| Equity | $368.0M | · |
| Net debt / equity | −0.08× | · |
| Current ratio | 2.49× | 1.28× |
| Revenue CAGR 5y | 8.2% | −7.4% |
| Profit CAGR 5y | · | · |
MYGN bills 13.4× the revenue of TRIB, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MYGN | TRIB |
|---|---|---|
| FY2024 | $837.6M | $61.6M |
| FY2023 | $753.2M | $56.8M |
| FY2022 | $678.4M | $62.5M |
| FY2021 | $690.6M | $81.1M |
| FY2020 | $557.1M | $102.0M |
| FY2019 | $638.6M | $90.4M |
| FY2018 | $851.1M | $97.0M |
| FY2017 | $743.7M | $99.1M |
| FY2016 | $728.7M | $99.6M |
| FY2015 | $740.5M | $100.2M |
Bottom line
| Fiscal year | MYGN | TRIB |
|---|---|---|
| FY2024 | $-127.3M | $-31.8M |
| FY2023 | $-263.3M | $-24.0M |
| FY2022 | $-112.0M | $-41.0M |
| FY2021 | $-27.2M | $875,000 |
| FY2020 | $-223.6M | $-6.4M |
| FY2019 | $-199.5M | $-28.9M |
| FY2018 | $4.6M | $-22.1M |
| FY2017 | $133.3M | $-40.3M |
| FY2016 | $17.4M | $-100.6M |
| FY2015 | $117.2M | $21.8M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +$776,045,000 | MYGN |
| FY2023 | +$696,368,000 | MYGN |
| FY2022 | +$615,879,000 | MYGN |
| FY2021 | +$609,451,000 | MYGN |
| FY2020 | +$455,120,000 | MYGN |
| FY2019 | +$548,165,000 | MYGN |
| FY2018 | +$754,065,000 | MYGN |
| FY2017 | +$644,560,000 | MYGN |
| FY2016 | +$629,089,000 | MYGN |
| FY2015 | +$640,305,000 | MYGN |
MYGN has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +35.5 pp | MYGN |
| FY2023 | +29.9 pp | MYGN |
| FY2022 | +53.2 pp | MYGN |
| FY2021 | −1.7 pp | TRIB |
| FY2020 | −34.3 pp | TRIB |
| FY2019 | +0.8 pp | MYGN |
| FY2018 | +23.9 pp | MYGN |
| FY2017 | +56.9 pp | MYGN |
| FY2016 | +41.1 pp | MYGN |
| FY2015 | −6.3 pp | TRIB |
The higher net margin has changed hands between MYGN and TRIB over this period.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TRIB's net margin has been more volatile than MYGN's over the 10 comparable fiscal years — 27.4 percentage points of standard deviation against 19.5.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MYGN and TRIB over these 10 fiscal years — MYGN led in 7 and TRIB in 3.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TRIB's return on equity has been more volatile than MYGN's over the 5 comparable fiscal years — 41.4 percentage points of standard deviation against 13.2.
5 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
MYGN led in return on equity in every one of the 5 comparable fiscal years — a structural lead, not a recent swing.
5 of 18 comparable fiscal years — a year missing data on either side is not counted.